Insights into Renal Cell Carcinoma (RCC) 2020 (Northeast)
Current treatment practice attitudes toward therapy of unresectable advanced renal cell carcinoma (RCC), recently introduced and upcoming agents
Northeast – November 16, 2020
Faculty Chair
Bradley A. McGregor, MD
Dana-Farber Cancer Institute, Boston, M
REPORT SNAPSHOT
- A roundtable discussion, moderated by an Axess Oncology Network physician, focusing on treatment of advanced RCC was held on November 16, 2020, in a virtual setting
- Disease state and data presentations were developed in conjunction with Bradley A. McGregor, MD, a medical expert from Dana-Farber Cancer Institute
- The group of advisors comprised 10 community oncologists from the northeast United States
- Insights on the following therapies were obtained: sunitinib, pazopanib, cabozantinib, axitinib, lenvatinib, ipilimumab, pembrolizumab, nivolumab, avelumab, everolimus, and combinations of these drugs
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection was accomplished through use of audience response system (ARS) questioning and moderated discussion
- Attendees of the roundtable represented community oncologists from Maine, Massachusetts, New Hampshire, and Vermont
